PDS Biotechnology Corporation

NASDAQ:PDSB

3.28 (USD) • At close November 7, 2024
Bedrijfsnaam PDS Biotechnology Corporation
Symbool PDSB
Munteenheid USD
Prijs 3.28
Beurswaarde 120,768,944
Dividendpercentage 0%
52-weken bereik 2.53 - 6.85
Industrie Biotechnology
Sector Healthcare
CEO Dr. Frank K. Bedu-Addo Ph.D.
Website https://www.pdsbiotech.com

An error occurred while fetching data.

Over PDS Biotechnology Corporation

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also

Vergelijkbare Aandelen

Spok Holdings, Inc. logo

Spok Holdings, Inc.

SPOK

16.76 USD

scPharmaceuticals Inc. logo

scPharmaceuticals Inc.

SCPH

4.32 USD

Acumen Pharmaceuticals, Inc. logo

Acumen Pharmaceuticals, Inc.

ABOS

3.17 USD

ProPhase Labs, Inc. logo

ProPhase Labs, Inc.

PRPH

1.43 USD

TFF Pharmaceuticals, Inc. logo

TFF Pharmaceuticals, Inc.

TFFP

1.63 USD

Sol-Gel Technologies Ltd. logo

Sol-Gel Technologies Ltd.

SLGL

0.591 USD

Sensus Healthcare, Inc. logo

Sensus Healthcare, Inc.

SRTS

6.54 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)